Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.435NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.445NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.124NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.384NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAQNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.3.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.569NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.524NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
A.23NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.596.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.473NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.595.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.76.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.38.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.38.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BM.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.501NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.226NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.546NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.194NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.429.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
P.1.9 (Gamma)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.25.1.1 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.203NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.157NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.176NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.3.4 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.391NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.393NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.432NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.388NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
P.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.48NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.112NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.274NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.515NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.258.23NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.370NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.118NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.137NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.309NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.632NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.72NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.108NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.332NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.50NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.494NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.167NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.267NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.554NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used